Markets:

Overview

News

Currencies

International

Treasuries

Stoke Therapeutics, Inc. - Common Stock (NQ:STOK)

24.25 +0.98 (+4.23%)

Delayed Quote Updated: 10:04 AM EDT, Oct 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Stoke Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Expert Ratings for Stoke Therapeutics ↗

January 11, 2023

Via Benzinga

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023

January 09, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 04, 2023

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics Earnings Perspective: Return On Capital Employed ↗

December 26, 2022

Via Benzinga

Yum! Brands To Rally Around 20%? Here Are 10 Other Price Target Changes For Monday ↗

December 05, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

December 02, 2022

On Friday, 72 companies hit new 52-week lows.

Via Benzinga

Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

December 02, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting

November 29, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Tuesday ↗

November 22, 2022

During Tuesday's trading, 160 companies set new 52-week lows.

Via Benzinga

BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday ↗

November 17, 2022

U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Thursday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday ↗

November 15, 2022

Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus...

Via Benzinga

Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session ↗

November 14, 2022

Gainers Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target.

Via Benzinga

Stoke Therapeutics Stock Falls Post Early Efficacy Data From Lead Dravet Syndrome Program ↗

November 14, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

November 14, 2022

Monday saw 33 companies set new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 14, 2022

Gainers

Via Benzinga

Hasbro, Ascendis Pharma, Coinbase Global And Some Other Big Stocks Moving Lower On Monday ↗

November 14, 2022

U.S. stocks traded mixed, with the Nasdaq gaining more than 50 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

November 14, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-001 in Children and Adolescents with Dravet Syndrome

November 10, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 25, 2022

Via Benzinga

Stoke Therapeutics Commences Initial-Stage Optic Nerve Disorder Study ↗

August 25, 2022

Stoke Therapeutics (NASDAQ: STOK) has enrolled first patient in a prospective natural history study of people ages 8 to 60 who are living with autosomal dominant optic atrophy (ADOA).

Via Benzinga

Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)

August 25, 2022

From Stoke Therapeutics

Via Business Wire

7 Stocks Due for a Stunning Short Squeeze ↗

August 09, 2022

If you can handle the heat, these ideas could potentially cook up some massive profits.

Via InvestorPlace

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

August 08, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference

June 01, 2022

From Stoke Therapeutics, Inc.

Via Business Wire

Stocks That Hit 52-Week Lows On Friday ↗

May 27, 2022

During Friday's session, 59 stocks hit new 52-week lows.

Via Benzinga

Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday ↗

August 09, 2022

Gainers Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday.

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

May 26, 2022

On Thursday, 94 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

May 25, 2022

On Wednesday, 215 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

May 24, 2022

On Tuesday, 540 companies set new 52-week lows.

Via Benzinga

Recap: Stoke Therapeutics Q1 Earnings ↗

May 10, 2022

Stoke Therapeutics (NASDAQ:STOK) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Stoke Therapeutics reported...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.